中文

Krystal Biotech falls 11% as pipeline delays overshadow a beat

By · AI-assisted, human-reviewed and edited · · 8 sources · Fact-checked · 4 min read

Why is Krystal stock down today?

Krystal Biotech beat profit estimates and approved a $400 million share buyback on Monday, but it moved expected KB803 and KB407 results into 2027 and delayed enrollment milestones for KB801 and a KB707 lung cancer cohort. The shares fell 11%, on a day the broader market also fell.

What it means

What changed
Krystal's releases show later results for KB803 and KB407, delayed enrollment milestones for KB801 and KB707, and a lower expense forecast.
What hasn't changed
Krystal reported 30% Vyjuvek sales growth to $127.3 million, a profitable quarter, and about $1.2 billion in cash and investments at September 30.
Next · Before year-end 2026
Krystal expects interim results from its KB111 study in Hailey-Hailey disease, a genetic skin condition.
Move
▼ 11%
Price
$332.29 → $295.90
Value lost
~$1.1B
Q3 Vyjuvek revenue
$127.3M (+30%)
Buyback approved
$400M
Intraday low
▼ 15%

Prices: Nasdaq official close, Nov 2, 2026 · Company data: 10-Q, Sep 30, 2026 · What these numbers mean

Nasdaq official closing prices on Oct 30 and Nov 2, 2026. Value lost is our estimate, using the 29.6 million shares Krystal reported outstanding on Oct 28, 2026.

Snapshot at the Nov 2, 2026 close

Enterprise value
$7.6B
Price/sales
18.7×
EV/sales
16.1×
P/E
38.9×
Price/FCF
28.3×
Revenue growth
+26%
Net cash
$1.2B

Our calculation from the company's filings (latest: 10-Q for the quarter to Sep 30, 2026, filed Nov 2, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Sep 30, 2026. Price $295.90 (Nasdaq official close); 29.6 million shares (common shares on the cover page of the 10-Q filed Nov 2, 2026). n/m = not meaningful (e.g. negative earnings).

What happened

Krystal Biotech reported a quarter that beat estimates and announced a buyback, but the shares fell after it pushed several expected trial results into 2027.

  • Krystal released third-quarter results before the market opened on Monday, Nov 2, with a call at 8:30 a.m. ET. Shares were down 3.7% before the open, Investing.com reported.
  • The stock closed at $295.90, down 11.0% from $332.29, after falling as low as $281.40 (Nasdaq; Yahoo Finance). We estimate the drop erased about $1.1 billion of its roughly $9.8 billion market value.
  • The SPDR S&P Biotech ETF (XBI), a sector benchmark, fell 2.5%, while the Nasdaq Composite fell 1.1% and the S&P 500 0.5% (Yahoo Finance).
  • Krystal’s shares were still up about 20% this year, from $246.54 at the end of 2025 (Yahoo Finance).

The results

The quarter itself was ahead of estimates, as reported by Investing.com; company figures are from Krystal’s release.

Q3 2026 Compared with
Vyjuvek revenue $127.3 million (+30%) About $126.8 million expected
Diluted earnings per share $2.05 About $1.84 expected
Net income $63.1 million $79.4 million a year earlier, which included an income-tax benefit
Cash and investments $1.2 billion
  • Net income fell because the year-earlier quarter included an income-tax benefit; pretax income rose to $80.1 million from $48.0 million, according to Krystal’s financial statements.
  • Vyjuvek is Krystal’s gene therapy for dystrophic epidermolysis bullosa (DEB), a genetic skin disease, applied directly to wounds. It is approved in the US, Europe and Japan. Krystal said pricing talks were complete in Germany and Italy; it now expects an Italian launch in early 2027, versus before year-end previously.
  • Krystal cut its 2026 forecast for combined research, development, selling and administrative expenses, excluding stock-based compensation, to $155–165 million from $175–195 million.
  • The board authorized up to $400 million of share buybacks, which Krystal expects to make opportunistically over the next two years.

What was delayed

Several milestones Krystal had expected by the end of 2026 moved into 2027, comparing its Aug 2026 and Nov 2 releases: results for two programs and enrollment targets for two others.

Program August 2026 November 2, 2026
KB803, eye abrasions in DEB (late-stage IOLITE trial) Initial main results in Q4 2026 Last patient visit in Feb 2027, results shortly after
KB801, neurotrophic keratitis, a condition caused by damage to the cornea’s nerves (late-stage EMERALD-1 trial) Finish enrolling about 60 patients before year-end Finish enrolling and report initial main results in 2027
KB407, cystic fibrosis Interim results before year-end Interim results in the first half of 2027
KB707, lung cancer (chemotherapy cohort) Finish enrolling later in 2026 About 70 patients dosed by mid-2027
  • Krystal said EMERALD-1 enrollment was slower than planned because of narrow eligibility criteria and the difficulty of enrolling a trial that compares treatment with an inactive substitute when an approved treatment already exists. It added three patients to the KB803 trial, replacing two who withdrew for reasons unrelated to safety.
  • The KB111 study in Hailey-Hailey disease, a genetic skin condition, is still expected to report interim results before year-end.

Why the market reacted this way

The coverage we found linked the drop to the pipeline timing rather than to the quarter: Seeking Alpha’s headline said the stock fell as data from pipeline programs were pushed to 2027. The shares were down 3.7% before the open, Investing.com reported, and fell further during the day. The announcement alone does not establish how much each development contributed.

  • The update delayed milestones for four programs, including two eye trials intended to support approval applications. It also lowered the full-year expense forecast.
  • The broader market also declined that day.

Does this change Krystal’s future?

What did NOT change

  • Vyjuvek keeps growing, and Krystal remains profitable, with about $1.2 billion of cash and investments and no debt on its balance sheet.
  • The programs are delayed, not stopped: Krystal still plans studies intended to support approval applications for KB407 and KB111 in 2027.

What DID change

  • Investors will wait longer for the next late-stage data, with KB803 results now expected after February 2027 and KB801 results in 2027.

Our read

Vyjuvek sales continued to grow, while several trial milestones moved later. Krystal still plans to advance these programs, but investors will wait longer for evidence of whether they work, and it has not given a more precise 2027 date for KB801 results.

What to watch next

Before year-end 2026
Interim results from the KB111 study in Hailey-Hailey disease, a genetic skin condition; that timing did not change.
February 2027
Krystal expects the final KB803 patient visit in February 2027, with initial main results shortly afterward.
First half of 2027
Krystal expects interim KB407 results in cystic fibrosis in the first half of 2027 and an FDA meeting on KB111 in the first quarter.
2027
Krystal expects to finish enrolling EMERALD-1, its KB801 eye trial, and report initial main results in 2027.

Quick questions

Did Krystal Biotech miss its earnings?

No. Diluted earnings per share were $2.05 against about $1.84 expected, and revenue of $127.3 million was slightly above the roughly $126.8 million estimate, Investing.com and StreetInsider reported.

Which programs were delayed?

Expected results for KB803 (an eye trial) and KB407 (cystic fibrosis) moved into 2027, and enrollment milestones for KB801 (an eye trial) and a KB707 lung cancer cohort slipped, according to Krystal's Q2 and Q3 releases.

What is the buyback?

Krystal's board authorized up to $400 million of share repurchases, which the company expects to make opportunistically over the next two years.

About Krystal: Website (external site)Investor relations (external site)SEC filings (external site)

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.